Immunitybio Inc
IBRX2.380USD
+0.010+0.42%
交易中 （美东）报价延迟15分钟
2.03B总市值
亏损市盈率 TTM
关于 Immunitybio Inc 公司
Immunitybio, Inc. 是一家垂直整合的临床阶段生物技术公司，致力于开发能够增强自然免疫系统以对抗癌症和传染病的疗法和疫苗。该公司利用其专有平台来增强免疫系统的先天性和适应性分支，开发先进的疗法和疫苗以对抗泌尿系统癌症和其他癌症以及传染病。其平台及其相关候选产品旨在通过以协调的方式激活先天免疫系统（包括 NK 细胞、树突状细胞和巨噬细胞）以及适应性免疫系统（包括 B 细胞和 T 细胞）来攻击癌症和传染性病原体。其生物候选产品开发平台包括抗体-细胞因子融合蛋白、DNA、RNA 和重组蛋白疫苗以及细胞疗法。其领先的生物商业候选产品 Anktiva 是一种 IL-15 超激动剂抗体-细胞因子融合蛋白。
公司简介
公司代码IBRX
公司名称Immunitybio Inc
上市日期Jul 28, 2015
CEOMr. Richard Adcock
员工数量680
证券类型Ordinary Share
年结日Jul 28
公司地址3530 John Hopkins Court
城市SAN DIEGO
上市交易所NASDAQ Global Select Consolidated
国家United States of America
邮编92121
电话18446965235
网址https://immunitybio.com/
公司代码IBRX
上市日期Jul 28, 2015
CEOMr. Richard Adcock
公司高管
名称
名称/职务
职务
持股
持股变动
Dr. Patrick Soon-Shiong, M.D.
Dr. Patrick Soon-Shiong, M.D.
Executive Chairman of the Board, Global Chief Scientific and Medical Officer
Executive Chairman of the Board, Global Chief Scientific and Medical Officer
35.16M
--
Mr. Richard Adcock
Mr. Richard Adcock
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
334.42K
--
Mr. Michael D. Blaszyk
Mr. Michael D. Blaszyk
Independent Director
Independent Director
265.58K
--
Ms. Cheryl L. Cohen
Ms. Cheryl L. Cohen
Lead Independent Director
Lead Independent Director
200.62K
--
Dr. Linda Maxwell, M.D.
Dr. Linda Maxwell, M.D.
Independent Director
Independent Director
--
--
Mr. David Sachs
Mr. David Sachs
Chief Financial Officer
Chief Financial Officer
--
--
Dr. Barry J. Simon, M.D.
Dr. Barry J. Simon, M.D.
Chief Corporate Affairs, Director
Chief Corporate Affairs, Director
--
--
Ms. Christobel E. Selecky
Ms. Christobel E. Selecky
Independent Director
Independent Director
--
--
Gen. (Retd.) Wesley Clark
Gen. (Retd.) Wesley Clark
Independent Director
Independent Director
--
--
名称
名称/职务
职务
持股
持股变动
Dr. Patrick Soon-Shiong, M.D.
Dr. Patrick Soon-Shiong, M.D.
Executive Chairman of the Board, Global Chief Scientific and Medical Officer
Executive Chairman of the Board, Global Chief Scientific and Medical Officer
35.16M
--
Mr. Richard Adcock
Mr. Richard Adcock
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
334.42K
--
Mr. Michael D. Blaszyk
Mr. Michael D. Blaszyk
Independent Director
Independent Director
265.58K
--
Ms. Cheryl L. Cohen
Ms. Cheryl L. Cohen
Lead Independent Director
Lead Independent Director
200.62K
--
Dr. Linda Maxwell, M.D.
Dr. Linda Maxwell, M.D.
Independent Director
Independent Director
--
--
Mr. David Sachs
Mr. David Sachs
Chief Financial Officer
Chief Financial Officer
--
--
收入明细
单位: USD更新时间: 7月6日 周日
单位: USD更新时间: 7月6日 周日
FY2024
FY2023
FY2022
FY2021
暂无数据
地区USD
名称
营收
占比
United States
14.21M
96.40%
Europe
531.00K
3.60%
业务
地区
暂无数据
股东统计
更新时间: 5月16日 周五
更新时间: 5月16日 周五
持股股东
股东类型
持股股东
持股股东
占比
Cambridge Equities, L.P.
69.59%
Soon-Shiong (Patrick)
3.98%
The Vanguard Group, Inc.
2.30%
BlackRock Institutional Trust Company, N.A.
1.31%
State Street Global Advisors (US)
0.86%
Other
21.95%
持股股东
持股股东
占比
Cambridge Equities, L.P.
69.59%
Soon-Shiong (Patrick)
3.98%
The Vanguard Group, Inc.
2.30%
BlackRock Institutional Trust Company, N.A.
1.31%
State Street Global Advisors (US)
0.86%
Other
21.95%
股东类型
持股股东
占比
Corporation
69.59%
Investment Advisor
5.18%
Individual Investor
4.48%
Investment Advisor/Hedge Fund
2.27%
Hedge Fund
0.88%
Research Firm
0.88%
Bank and Trust
0.08%
Pension Fund
0.05%
Venture Capital
0.01%
Other
16.58%
机构持股
更新时间: 7月1日 周二
更新时间: 7月1日 周二
报告期
机构数
持股数
持股占比
持股变动
2025Q2
422
736.69M
83.41%
+107.95M
2025Q1
440
618.65M
87.38%
-10.66M
2024Q4
423
621.25M
74.01%
+7.18M
2024Q3
400
607.11M
84.02%
-2.53M
2024Q2
394
600.23M
83.10%
-13.23M
2024Q1
370
604.61M
90.46%
-1.82M
2023Q4
363
595.85M
89.24%
+717.13K
2023Q3
366
588.92M
88.35%
+213.08M
2023Q2
362
368.64M
84.54%
-18.27M
2023Q1
371
365.32M
90.28%
-6.95M
查看更多
股东持股明细
名称
持股数
占比
持股变动
变动比例
公告日期
Cambridge Equities, L.P.
614.63M
69.64%
+117.19M
+23.56%
Apr 21, 2025
Soon-Shiong (Patrick)
35.16M
3.98%
--
--
Apr 21, 2025
The Vanguard Group, Inc.
20.30M
2.3%
+3.01M
+17.38%
Mar 31, 2025
BlackRock Institutional Trust Company, N.A.
11.61M
1.32%
-454.93K
-3.77%
Mar 31, 2025
State Street Global Advisors (US)
7.58M
0.86%
-2.20M
-22.50%
Mar 31, 2025
Geode Capital Management, L.L.C.
4.29M
0.49%
+448.50K
+11.68%
Mar 31, 2025
Woodline Partners LP
3.45M
0.39%
+2.66K
+0.08%
Mar 31, 2025
Simon (Barry J. M.D.)
3.24M
0.37%
--
--
Apr 21, 2025
Citi Investment Research (US)
2.71M
0.31%
+2.33M
+605.88%
Mar 31, 2025
Tang Capital Management, LLC
2.33M
0.26%
-480.86K
-17.09%
Mar 31, 2025
查看更多
持股ETF
更新时间: 8月2日 周六
更新时间: 8月2日 周六
机构名称
占比
Virtus LifeSci Biotech Products ETF
1.59%
iShares Genomics Immunology and Healthcare ETF
0.56%
Invesco Nasdaq Biotechnology ETF
0.26%
ProShares Ultra Nasdaq Biotechnology
0.26%
First Trust Small Cap Growth AlphaDEX Fund
0.19%
SPDR S&P Biotech ETF
0.17%
Direxion Daily S&P Biotech Bull 3X Shares
0.1%
Goldman Sachs Innovate Equity ETF
0.09%
First Trust Small Cap Core Alphadex Fund
0.05%
JPMorgan BetaBuilders US Small Cap Equity ETF
0.04%
查看更多
Virtus LifeSci Biotech Products ETF
占比1.59%
iShares Genomics Immunology and Healthcare ETF
占比0.56%
Invesco Nasdaq Biotechnology ETF
占比0.26%
ProShares Ultra Nasdaq Biotechnology
占比0.26%
First Trust Small Cap Growth AlphaDEX Fund
占比0.19%
SPDR S&P Biotech ETF
占比0.17%
Direxion Daily S&P Biotech Bull 3X Shares
占比0.1%
Goldman Sachs Innovate Equity ETF
占比0.09%
First Trust Small Cap Core Alphadex Fund
占比0.05%
JPMorgan BetaBuilders US Small Cap Equity ETF
占比0.04%
分红派息
近5年累计派现
0.00
美元
公告日期
分红计划
股权登记日
现金发放日
除权除息日
暂无数据
拆合股
公告日期
类型
比率
暂无数据
公告日期
类型
比率
暂无数据
